Novel combinations with programmed cell death 1 inhibitor for incurable recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC): is cabozantinib a front runner?

Priyanka Bhateja, Marcelo Bonomi, Claire Verschraegen